Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06455449RecruitingPhase 3
Injectable anifrolumab for polymyositis or dermatomyositis
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
Phoenix, ArizonaAges 18–75 - NCT06457503RecruitingPhase 4
Toripalimab plus chemo for advanced nasopharyngeal cancer
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
Little Rock, ArkansasAges 12 years+ - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Duarte, CaliforniaAges 18 years+ - NCT06463925Recruiting
Acne cream for face and trunk acne
This study tests a new acne cream (Effaclar Duo+M) for people with mild to moderate acne on their face and trunk. It aims to see if the cream helps clear acne and is gentle on the skin.
Rio de JaneiroAges 18 years+ - NCT06469281RecruitingPhase 1
A new immune cell therapy for recurring ovarian cancer
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
Boston, MassachusettsAges 18 years+ - NCT06470048RecruitingPhase 2
Testing Ianalumab for Diffuse Cutaneous Systemic Sclerosis
This trial tests a new drug called ianalumab for people with diffuse cutaneous systemic sclerosis (a type of scleroderma affecting the skin and internal organs). It aims to see if the drug can help control the disease activity and reduce skin thickening.
Mesa, ArizonaAges 18–70 - NCT06471829RecruitingPhase 2
Study of Lu AG13909 for adults with Cushing's disease
This study tests a new medicine called Lu AG13909 for adults with Cushing's disease caused by a pituitary tumor. It aims to see if the medicine can lower cortisol levels and help control the disease.
Ann Arbor, MichiganAges 18–70 - NCT06473246Recruiting
Safety and effects of a new stress supplement in healthy adults
This trial tests a new supplement (VL-SE-01) to see if it is safe and how well it works for people with a stressed lifestyle. If you are a generally healthy adult between 18 and 55 and feel stressed, you may be able to join.
Dombivali, MaharashtraAges 18–55 - NCT06474169Recruiting
T-cell study in long-term kidney failure
This study is looking at how immune cells called T-cells work in people with long-term kidney failure. It tests whether these cells can be changed in the lab to help treat the condition.
OrléansAges 18 years+ - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Los Angeles, CaliforniaAges 18 years+ - NCT06477809Recruiting
Testing a device to help blind people with daily tasks
This trial tests a new device (ARIA) that helps people who are blind navigate daily tasks. If you have no light perception or only light perception, use a long cane, and are comfortable with a smartphone, you may be able to take part in 4 sessions in Sydney.
Sydney, New South WalesAges 18 years+ - NCT06479616Recruiting
Long-term follow-up for CS-101 recipients
This study checks on participants who previously received the experimental treatment CS-101. It aims to track their health over time to see how safe and effective the treatment is in the long run.
Shanghai, Shanghai MunicipalityAges 3–17 - NCT06481618Recruiting
Stress and ventilation bag use by healthcare workers
This study looks at how stress affects healthcare workers' ability to use a manual ventilation bag correctly. If you are a doctor, nurse, or other healthcare professional who may need to give manual ventilation, you may be able to join.
Clermont-FerrandAges 18 years+ - NCT07692165RecruitingPhase 1/Phase 2
Testing INT-210 capsules for active ulcerative colitis
This trial tests an experimental capsule called INT-210 for people with active ulcerative colitis (UC) who haven't improved enough with standard treatments. It aims to see if the drug can help control symptoms and improve the condition.
Guangzhou, GuangdongAges 18–75 - NCT07013747RecruitingPhase 1/Phase 2
Acne mRNA vaccine for mild acne
This trial tests an mRNA vaccine designed to treat mild facial acne. It aims to see if the vaccine is safe and effective at reducing acne lesions.
Encino, CaliforniaAges 18–45 - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Gilbert, ArizonaAges 18 years+ - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
Springdale, ArkansasAges 18 years+ - NCT03603223RecruitingPhase 2
Pembrolizumab for abnormal mouth patches that may become cancer
This Phase 2 trial studies pembrolizumab (an immune medicine) for leukoplakia and related abnormal mouth patches with moderate/severe pre-cancer changes. It aims to see whether the treatment can shrink or control the lesions when surgery or radiation isn’t an option.
La Jolla, CaliforniaAges 18 years+ - NCT07220616RecruitingPhase 1/Phase 2
DS3790a for people with blood cancers
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
New York, New YorkAges 18 years+ - NCT07621809RecruitingPhase 3
Ianalumab versus placebo for Sjögren's disease with high symptom burden
This study tests whether a new drug called ianalumab can reduce dry mouth and other symptoms in people with Sjögren's disease—a condition where the immune system attacks moisture-producing glands. Participants will receive either ianalumab or a placebo (inactive injection) over 52 weeks to see if the drug helps.
Charlotte, North CarolinaAges 18 years+ - NCT07489885RecruitingPhase 2
Study of D-2570 for moderate to severe plaque psoriasis
This trial tests an experimental drug, D-2570, for people with moderate to severe plaque psoriasis. It aims to see if the medication can safely improve skin symptoms.
Birmingham, AlabamaAges 18–70 - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Sarasota, FloridaAges 18 years+ - NCT07063342RecruitingPhase 1
Study of new drug versions in healthy adults
This study is testing new versions of a drug (called KarX and KarT) in healthy adults to see how the body handles them. Researchers will also look at how food affects the drug when taken multiple times.
Nottingham, NottinghamshireAges 18–55 - NCT07584876RecruitingPhase 1
Safety study of a new blood clotting medicine in healthy adults
This is an early-stage safety study testing a new experimental medicine that affects blood clotting in people with no serious health conditions. Researchers want to make sure the medicine is safe and well-tolerated before testing it in patients who need it.
Perth, Western AustraliaAges 18–65
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,211 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.